ZYBERNO
Stock Report
Updated Jun 5, 2026

iCAD INC (ICAD)

Healthcare • NASDAQ

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
21.0/100
POOR BUSINESS
iCAD INC (ICAD) scores 21/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-17.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (-30.5%)
Return on Capital (Capital Efficiency):CRITICAL (-39.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

iCAD INC (ICAD) stock report — Zyberno Score 21/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ICAD generated -$2.77M in Owner Earnings. Capital was deployed as follows: $64.00K invested in capital expenditures. Reinvestment rate: 1.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$0.00

Enterprise Metrics (1)

Enterprise Value:-$19.49M
B. Profitability Assessment

Return Metrics (5)

ROA:-13.7%
Reinvestment Rate:1.7%
Fundamental Growth Rate (g):-0.7%

Margin Analysis (3)

Operating Margin Ttm:-30.5%
Net Margin Ttm:-26.8%
Ebitda Margin:-23.9%

TTM Performance (3)

Gross Margin Ttm:85.6%
Operating Margin Ttm:-30.5%
Net Margin Ttm:-26.8%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:-999.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:17.8%
Latest Earnings Filed:2023-03-31

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-19.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.66x
Quick Ratio:3.57x
Cash Ratio:2.60x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:20,430,000.00
Cash And Cash Equivalents:20,032,000.00
Long Term Debt:$307.00K
Net Debt:-$19.49M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $19.53M
Linear Growth: -19.0%
📊 Click to view full ICAD Revenue analysis & methodology →
Cost Of Revenue Ttm:$2.82M

Profitability Breakdown (2)

Gross profit TTM: $16.71M
Linear Growth: -11.6%
📊 Click to view full ICAD Gross Profit analysis & methodology →
-$5.96M

Bottom Line Performance (3)

-$5.23M
Income Before Tax:-$5.13M
Ebitda Ttm:-4,667,000.00

Operating Expenses (5)

Operating Expenses:22,667,000.00
R And D Expense:6,578,000.00
Sga Expense:7,980,000.00
Income Tax Expense:$94.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:135.0%
Sga To Revenue Percentage:163.7%
Ebitda Margin:-23.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$39.47M
Current Assets:$28.12M
Ppe Net:1,814,000.00
Goodwill:8,362,000.00
Intangible Assets:$90.00K

Liability Structure (4)

Total Liabilities:8,684,000.00
Current Liabilities:7,692,000.00
Long Term Debt:$307.00K
Short Term Debt:$234.00K

Equity & Capital (3)

Equity:$30.79M
Retained Earnings:-$278.13M
Common Stock:60,000,000.00

Working Capital Items (3)

Accounts Receivable:6,627,000.00
Inventory:694,000.00
Accounts Payable:1,136,000.00

Special Items (2)

Contract Liabilities:4,852,000.00
Stock Based Compensation:602,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.71M-$2.77M

Investment Activities (2)

Investing Cash Flow:$431.00K
Capital Expenditures Ttm:64,000.00

Financing Activities (3)

Financing Cash Flow:$2.34M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,335,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:1,289,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.19
-$0.54
Earnings Per Share Ttm:-$0.20

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.73
Operating Cash Flow Per Share:-$0.15

Book Value & Capital (2)

Book Value Per Share:$1.15
Cash Per Share:0.75

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.51x
Working Capital Turnover Ttm:0.96x

Receivables Management (2)

Receivables Turnover Ttm:2.95x
Days Sales Outstanding Ttm:123.87

Inventory Management (2)

Inventory Turnover Ttm:4.06x
Days Inventory Outstanding Ttm:89.92

Payables & Cash Cycle (2)

Days Payable Outstanding:147.19
Cash Conversion Cycle:66.60
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$2.77M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.7%
Fundamental Growth Rate (g):-0.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-19.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-11.6%
Book Value Growth Rate (Linear):-9.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:ICAD
Company Name:iCAD INC
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:26.71M
Shares Outstanding Basic:26.71M
Shares Outstanding Diluted:25.20M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-05 16:18:57 UTC
Data Timestamp:2026-06-05T16:18:57.038194
Scroll to Top